Human RANK & NF-κB Reporter Recombinant Cell Line, HEK293 (CAT#: IOC-LX139)

Creative Biolabs has developed several immune checkpoint stable cell Lines expressing the most popular immune checkpoints to accelerate clients' immunotherapy discovery and clinical translation. Recombinant HEK-293 cells expressing firefly luciferase gene under the control of Nuclear factor-κB (NF-κB) with constitutive expression of human RANK (Receptor activator of nuclear factor-κB; TNFRSF11A; ref. seq. NM_003839.2). Which can be used in binding assays and functional assay.

Stable cell lines for increased reliability and reproducibility;
Protein expression at the cell surface validated by FACS or WB;

Screen for inhibitors of RANKL/RANK signaling in a cellular context.

Human

HEK293

RANK & NF-κB Reporter

RANK/RANKL/OPG pathway plays a significant role in osteoclast maturation, which are the major cells in charge of bone resorption. If RANKL binds to the receptor RANK instead of binding to its decoy receptor Osteoprotegerin (OPG), it activates the NF-κB pathway to promote osteoclast survival and proliferation, resulting in the resorption of bone. Therefore, abnormal production of RANKL or OPG can cause osteoporosis and other bone-related disorders, making the RANKL/RANK signaling pathway a valuable target for drug development.